Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) has been assigned a $6.00 price objective by Maxim Group in a research note issued to investors on Tuesday. The firm presently has a “sell” rating on the biotechnology company’s stock. Maxim Group’s target price suggests a potential downside of 57.60% from the stock’s previous close.

A number of other equities research analysts have also recently commented on MNTA. Zacks Investment Research cut shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 5th. JPMorgan Chase & Co. reduced their target price on shares of Momenta Pharmaceuticals from $21.00 to $15.00 and set an “overweight” rating for the company in a research report on Friday, August 5th. Aegis initiated coverage on shares of Momenta Pharmaceuticals in a research report on Tuesday, November 22nd. They issued a “hold” rating and a $15.00 target price for the company. Stifel Nicolaus set a $20.00 target price on shares of Momenta Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday. Finally, Barclays PLC upgraded shares of Momenta Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $13.00 to $19.00 in a research report on Tuesday, October 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $16.10.

Analyst Recommendations for Momenta Pharmaceuticals (NASDAQ:MNTA)

Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) opened at 14.15 on Tuesday. Momenta Pharmaceuticals has a 52-week low of $7.86 and a 52-week high of $18.26. The stock’s market capitalization is $975.74 million. The firm has a 50-day moving average of $12.43 and a 200 day moving average of $11.73.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its quarterly earnings data on Wednesday, November 2nd. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.29) by $0.03. The business had revenue of $299.14 million for the quarter, compared to the consensus estimate of $25.68 million. Momenta Pharmaceuticals had a negative net margin of 93.75% and a negative return on equity of 26.55%. The company’s revenue was up 2067.7% compared to the same quarter last year. During the same period last year, the firm posted ($0.44) earnings per share. Equities research analysts forecast that Momenta Pharmaceuticals will post ($1.16) EPS for the current fiscal year.

WARNING: “Momenta Pharmaceuticals Inc. (MNTA) PT Set at $6.00 by Maxim Group” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another site, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this story can be accessed at http://www.dailypolitical.com/2016/12/01/momenta-pharmaceuticals-inc-mnta-pt-set-at-6-00-by-maxim-group.html.

In other Momenta Pharmaceuticals news, President Craig A. Wheeler sold 5,880 shares of Momenta Pharmaceuticals stock in a transaction dated Tuesday, November 22nd. The shares were sold at an average price of $13.68, for a total transaction of $80,438.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 6.10% of the company’s stock.

Several large investors have recently made changes to their positions in MNTA. Pacad Investment Ltd. bought a new stake in shares of Momenta Pharmaceuticals during the second quarter worth $103,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Momenta Pharmaceuticals during the second quarter worth $109,000. Jane Street Group LLC bought a new stake in shares of Momenta Pharmaceuticals during the second quarter worth $109,000. Profund Advisors LLC bought a new stake in shares of Momenta Pharmaceuticals during the third quarter worth $121,000. Finally, Mason Street Advisors LLC bought a new stake in shares of Momenta Pharmaceuticals during the second quarter worth $134,000. Institutional investors and hedge funds own 84.86% of the company’s stock.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection).

5 Day Chart for NASDAQ:MNTA

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.